This series covers in autobiographical accounts the first fifty years in the history of neuropsychopharmacology. The autobiographies in Volume I, (The Rise of Psychopharmacology and the Story of CINP) are from psychopharmacologists who began their professional careers in the 1950s and 1960s; in Volume II (The Triumph of Psychopharmacology and the Story of CINP), from those who started in the 1970s; in Volume III (From Psychopharmacology to Neuropsychopharmacology in the 1980s and the Story of CINP), who started in the 1980s; and in Volume IV (Reflections on Twentieth-Century Psychopharmacology), who started in the 1990s. At the core of each volume are personal accounts in which the contributions of the scientists, are at the center of the reflections, but also include several sections in which the reflections are focused on the mainstream of events, particular areas of research, individuals and organizations. The series was the extension of an effort by CINP's History Committee, during the chairmanship of Tom Ban, to document both the history of the College and the enire field. It was co-edited by Ban, David Healy and Edward Shorter. Its publication was supported by the College primarily from non-restricted publication grants received from Pierre Fabre, Janssen Pharmaceutica and Research Foundation,Inc., and Janssen Phamaceutica International in Collaboration with Organon International.

This series covers in autobiographical accounts the first fifty years in the history of neuropsychopharmacology. The autobiographies in Volume I, (The Rise of Psychopharmacology and the Story of CINP) are from psychopharmacologists who began their professional careers in the 1950s and 1960s; in Volume II (The Triumph of Psychopharmacology and the Story of CINP), from those who started in the 1970s; in Volume III (From Psychopharmacology to Neuropsychopharmacology in the 1980s and the Story of CINP), who started in the 1980s; and in Volume IV (Reflections on Twentieth-Century Psychopharmacology), who started in the 1990s. At the core of each volume are personal accounts in which the contributions of the scientists, are at the center of the reflections, but also include several sections in which the reflections are focused on the mainstream of events, particular areas of research, individuals and organizations. The series was the extension of an effort by CINP’s History Committee, during the chairmanship of Tom Ban, to document both the history of the College and the enire field. It was co-edited by Ban, David Healy and Edward Shorter. Its publication was supported by the College primarily from non-restricted publication grants received from Pierre Fabre, Janssen Pharmaceutica and Research Foundation,Inc., and Janssen Phamaceutica International in Collaboration with Organon International.

The Age of Psychopharmacology began with a brilliant rise in the 1950s, when for the first time science entered the study of drugs that affect the brain and mind. But, esteemed historian Edward Shorter argues that there has been a recent fall, as the field has seen its drug offerings impoverished and its diagnoses distorted by the "Diagnostic and Statistical Manual of Mental Disorders." The new drugs, such as Prozac, have been less effective than the old. The new diagnoses, such as "major depression," have strayed increasingly from the real disorders of most patients. Behind this disaster has been the invasion of the field by the pharmaceutical industry. This invasion has paid off commercially but not scientifically: There have been no new classes of psychiatry drugs in the last thirty years. Given that psychiatry's diagnoses and therapeutics have largely failed, the field has greatly declined from earlier days. Based on extensive research discovered in litigation, Shorter provides a historical perspective of change and decline over time, concluding that the story of the psychopharmacology is a story of a public health disaster.

Neuropsychopharmacology reviews the principles of pharmacology with a focus on the central nervous system and autonomic nervous system. Beyond autonomic and central nervous system pharmacology, this volume uniquely discusses psychiatric disorders and the pharmacological interventions that are available for conditions including depression, schizophrenia and anxiety disorders. With a focus on these specific body systems, readers will see end-of-chapter questions that offer real-world case studies, as well as multiple-choice questions for further learning. Beneficial features and content also include two extensive examination tests, which each contain 100 questions for better learning or to be used in teaching, and a glossary. Helpful appendices cover high-alert medications and toxicology effects on the nervous system. Each chapter will contain classifications of medications, pharmacokinetics, mechanism of action, clinical indications and toxicities. Describes pharmacology principles pertaining to the central and autonomic nervous system Identifies pharmacological interventions for psychiatric disorders including current evidence-based interventions for depression, schizophrenia and anxiety disorders Features chapter outlines, end-of-chapter questions, real-world case studies and examinations for deeper learning or teaching